B. Braun OEM Division - System-built Solutions. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

B. Braun OEM Division – System-built Solutions.

Expertise in contract manufacturing and infusion therapy products

B. Braun supplies healthcare markets worldwide and is employing approx. 48,000 individuals. Based on this expertise the B. Braun OEM Division serves the pharmaceutical and medical devices industry.

At B. Braun OEM we offer contract manufacturing for infusion, irrigation and volume replacement solutions as well as standard injectables, anesthetics and dermatological products like creams, gels and pomades. Depending on the product requirements, we can fill in containers of different sizes, shapes and materials.

Furthermore, we provide a wide range of infusion therapy products. We supply all that is needed to admixture and infuse or inject a drug. You can order standard products or a customized version.

Partnering with us provides you with complete outsourcing knowledge. Our project management teams are the experts for individual customer ideas.

We can handle manufacturing projects and will customize a product or set according to your detailed specifications.

Products:

  • Pharmaceutical Solutions
  • Medical Devices
  • Products for Disinfection and Hygiene

Project management services:

  • Customized Products (modified characteristics, private label etc.)
  • Customized Sets Pharmaceutical
  • Contract Manufacturing
  • Common Development

B. Braun Melsungen AG
Website: www.bbraunoem.com
E-mail: info-europe@bbraunoem.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here